MRK•benzinga•
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Summary
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 9, 2025 by benzinga